Medik8 Crystal Retinal Ceramide Eye 10 15ml
Wake up to a more youthful-looking eye area with fewer crow’s feet, reduced puffiness and visibly brightened dark circles.
This world-first, clinically proven nighttime eye cream contains next-generation retinAL (not retinol) which works 11x times faster than standard retinol to deliver remarkable visible results in just 1 use. Powerful results without irritating the delicate eye area.
Recommended by dermatologists worldwide, Crystal Retinal Ceramide Eye is available in 3 progressive strengths (that sit alongside our iconic Crystal Retinal ladder for the face), so you can keep experiencing ever-improving benefits.
KEY BENEFITS
-
Fewer Wrinkles in 1 Use
94% showed a clinical improvement to the look of wrinkles around the eyes in just 1 use.
**Proven via independent clinical study on Crystal Retinal Ceramide Eye 6 conducted over 12 weeks on 32 participants
-
Clinical Strength Results – Without Irritation
Expertly stabilised and optimised to deliver clinical strength, age-defying power alongside a gentle and nourishing experience for the delicate eye area.
-
Brighter, Smoother & Awakened Eye Area
Proven to visibly smooth, lift, and brighten the eye area overnight,* and clinically proven to visibly depuff the eye area in 1 use.**
*Proven via independent consumer study on Crystal Retinal Ceramide Eye 3 conducted over 6 weeks on 50 participants
**Proven via independent clinical study on Crystal Retinal Ceramide Eye 6 conducted over 12 weeks on 32 participants
-
Effective Results Until the Last Drop
Ensures visible results from the first drop to the very last, thanks to Medik8’s unique patented stability complex.
-
Customise Your Routine With 3 Strengths
Choose from 3 progressive strengths to suit every level of retinal user; from beginner to expert. Expertly optimised to be suitable for use on the delicate eye area.
Only logged in customers who have purchased this product may leave a review.
Be the first to review Medik8 Crystal Retinal Ceramide Eye 10 15ml
There are no reviews yet.